AMERITRADE
DATEK
Discover Brokerage
DLJDirect
E-Trade
Schwab




To receive immediate notification of research updates, enter your e-mail address here (ex: name@domain.com):


  AMBI Inc.
AMBI develops and commercializes nutritional products (nutraceuticals) for cardiovascular and other conditions, and develops pharmaceuticals for serious infectious diseases. The Company is aggressively pursuing a strategy of developing, in-licensing and acquiring unique nutritional products; an example is AMBI's recent acquisition of Nutrition 21, a leader in the development and marketing of essential mineral nutrients such as chromium picolinate and selenium. The Company has cut R&D expenses dramatically on its pharmaceuticals and plans to aggressively pursue corporate partnerships. Expected corporate milestones include: acquisition of rights to additional nutritional products and partners, filing of an IND on the leading drug candidate, and corporate partnering or alliances in the area of pharmaceuticals.

SMALLCAPS RESEARCH

SmallCaps Online LLC Reiterates BUY on AMBI Inc. Following Meeting with Management (06/21/99)


AMBI Reports Strong Revenue & Earnings Growth - REITERATING BUY (05/13/99)
Strong Fiscal 2Q99 Results (02/09/99)
Optimum/Lite Bites Acquisition Announced (01/26/99)
Increasing Earnings Estimates; Reiterate BUY (12/17/98)
UPDATED FINANCIAL MODEL (12/17/98)
AMBI Cleans Up Convertible Shares (11/30/98)
Fiscal 1Q99 Exceeds Expectations; Reiterate BUY (11/16/98)
Initial Opinion (10/13/98)
Financial Model